Controls without CAC (n = 121) Annual risk (n; 95% CI) | Persons with other CAC (n = 92) Annual risk (n; 95% CI) | Persons with bilateral vessel-outlining CACs (n = 25) Annual risk (n; 95% CI) | Log rank test | |
---|---|---|---|---|
Primary endpoint* | 2.6% (29; 1.7–3.4%) | 4.4% (38; 3.3–5.6%) | 7.0% (16; 5.0–9.0%) | < 0.001 |
Myocardial infarction | 0.6% (7; 0.2–1.1%) | 1.6% (12; 0.8–2.4%) | 0.7% (1; 0.0–2.0%) | 0.08 |
New-onset heart failure | 0.7% (8; 0.2–1.1%) | 0.7% (7; 0.1–1.2%) | 3.2% (7; 1.2–5.2%) | < 0.001 |
New-onset angina pectoris | 0.6% (6; 0.1–1.0%) | 0.5% (5; 0.0–1.1%) | 0.7% (1; 0.0–2.0%) | 0.93 |
New-onset symptomatic claudication | 0.1% (1; 0.0–0.3%) | 1.3% (10; 0.5–2.0%) | 0.9% (2; 0.0–2.0%) | 0.003 |
Stroke | 0.9% (10; 0.4–1.4%) | 0.8% (7; 0.2–1.5%) | 2.4% (5; 0.5–4.3%) | 0.08 |
Transient ischemic attack | 0.4% (5; 0.0–0.7%) | 0.9% (7; 0.3–1.6%) | 0.4% (1; 0.0–1.3%) | 0.38 |
Arterial revascularization | 0.8% (9; 0.3–1.4%) | 1.7% (13; 0.9–2.6%) | 2.9%(6; 0.9–4.9%) | 0.011 |
Vascular death† | 0.2% (1; 0.0–0.7%) | 1.0% (9; 0.4–1.7%) | 2.2% (5; 0.5–3.9%) | < 0.001 |
All-cause mortality‡ | 1.1% (18; 0.5–1.7%) | 2.6% (26; 1.7–3.6%) | 4.2% (11; 2.2–2.6%) | < 0.001 |